Who we are

As a leading global clinical-stage biopharmaceutical company, we strive to create transformative medicines to protect and improve people’s lives. Fueled by our proprietary RNA technology platform combined with two decades of science and manufacturing excellence, we are dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Event Highlight

Annual General Meeting 2021

June 24, 2021 | 02:00 P.M. CEST


Virtual

The Annual General Meeting (the “AGM”) of Shareholders of CureVac N.V. (the “Company”) will be held on Thursday, June 24, 2021, at 2:00 p.m. Central European Summer Time. The AGM will be held entirely virtually, without physical attendance of shareholders or others with meeting rights. You will not be able to vote during the AGM and your proxy to vote must be received no later than 5:59 a.m. Central European Summer Time on Tuesday, June 22, 2021.


The full manuscript"Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates"is available for download here:

Manuscript